XML 26 R15.htm IDEA: XBRL DOCUMENT v3.3.1.900
Note 9 - Segment Information
 9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
9
-
Segment Information
 
We have four reporting segments: Biological Indicators, Instruments, Continuous Monitoring and Cold Chain. The following tables set forth our segment information (in thousands):
 
 
 
Three Months Ended December 31, 2015
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
   $ 7,819     $ 8,260     $ 2,595     $ 1,239     $ 19,913  
                                         
Gross profit
   $ 4,869     $ 5,511     $ 1,254     $ 575     $ 12,209  
Selling expenses
     505       784       132       96       1,517  
    $ 4,364     $ 4,727     $ 1,122     $ 479       10,692  
Reconciling items
(1)
                                     (7,241 )
Earnings before income taxes
                                   $ 3,451  
 
 
 
Three Months Ended December 31, 2014
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
   $ 6,964     $ 8,216     $ 2,650     $ --     $ 17,830  
                                         
Gross profit
   $ 4,194     $ 5,412     $ 1,446     $ --     $ 11,052  
Selling expenses
     365       919       488       --       1,772  
    $ 3,829     $ 4,493     $ 958     $ --       9,280  
Reconciling items
(1)
                                     (5,567 )
Earnings before income taxes
                                   $ 3,713  
 
 
 
Nine Months Ended December 31, 2015
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
   $ 23,537     $ 25,819     $ 7,412     $ 3,079     $ 59,847  
                                         
Gross profit
   $ 15,157     $ 16,571     $ 3,246     $ 1,443     $ 36,417  
Selling expenses
     1,372       2,975       1,098       159       5,604  
    $ 13,785     $ 13,596     $ 2,148     $ 1,284       30,813  
Reconciling items
(1)
                                     (21,043 )
Earnings before income taxes
                                   $ 9,770  
 
 
 
Nine Months Ended December 31, 2014
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
   $ 19,822     $ 24,966     $ 7,982     $ --     $ 52,770  
                                         
Gross profit
   $ 12,029     $ 15,794     $ 4,057     $ --     $ 31,880  
Selling expenses
     766       3,093       1,318       --       5,177  
    $ 11,263     $ 12,701     $ 2,739     $ --       26,703  
Reconciling items
(1)
                                     (15,354 )
Earnings before income taxes
                                   $ 11,349  
 
(1)
Reconciling items include general and administrative, research and development, and other expenses.
 
 
 
 
December 31, 2015
 
 
March 31,
201
5
 
Total assets
                
Biological Indicators
   $ 54,285     $ 36,304  
Instruments
     50,436       44,401  
Continuous Monitoring
     25,965       31,558  
Cold Chain
     18,182       --  
Corporate and administrative
     6,813       5,057  
    $ 155,681     $ 117,320  
 
All long-lived assets are located in the United States except for $6,470,000 and $16,839,000 which are associated with our French and Canadian subsidiaries, respectively.
 
Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows (in thousands):
 
 
 
Three
M
onths
E
nded
December 31
,
 
 
Nine Months Ended
December 31,
 
 
 
201
5
 
 
2014
 
 
2015
 
 
2014
 
Net revenues from unaffiliated customers:
                                
United States
   $ 12,787     $ 11,423     $ 37,510     $ 29,612  
Foreign
     7,126       6,407       22,337       23,158  
    $ 19,913     $ 17,830     $ 59,847     $ 52,770  
 
No foreign country exceeds 10 percent of total revenues.